

Xiaomin Wan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150979/publications.pdf>

Version: 2024-02-01

39
papers

578
citations

932766

10
h-index

713013

21
g-index

39
all docs

39
docs citations

39
times ranked

422
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. <i>Clinical Rheumatology</i> , 2022, 41, 63-73.	1.0	4
2	Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 778505.	1.6	11
3	Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 860109.	1.6	10
4	Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 832215.	1.6	10
5	Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 849189.	1.6	5
6	Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study. <i>Pharmacoeconomics</i> , 2022, 40, 725-737.	1.7	5
7	Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure. <i>Rheumatology and Therapy</i> , 2021, 8, 775-791.	1.1	5
8	Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. <i>Advances in Therapy</i> , 2021, 38, 2379-2390.	1.3	2
9	Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China. <i>Rheumatology and Therapy</i> , 2021, 8, 863-876.	1.1	3
10	Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. <i>Advances in Therapy</i> , 2021, 38, 2571-2585.	1.3	6
11	First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis. <i>Advances in Therapy</i> , 2021, 38, 2447-2457.	1.3	11
12	Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684073.	1.3	9
13	Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer. <i>Advances in Therapy</i> , 2021, 38, 3399-3408.	1.3	5
14	Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , 2021, 38, 3962-3972.	1.3	11
15	First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. <i>Clinical Therapeutics</i> , 2021, 43, 1253-1264.e5.	1.1	2
16	Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%. <i>Advances in Therapy</i> , 2021, 38, 4354-4365.	1.3	7
17	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 580459.	1.6	11
18	Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies. <i>Frontiers in Pharmacology</i> , 2021, 12, 718014.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States. <i>Advances in Therapy</i> , 2021, 38, 5710-5720.	1.3	5
20	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 743765.	1.3	2
21	Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. <i>PLoS ONE</i> , 2021, 16, e0258605.	1.1	11
22	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression $\geq 50\%$. <i>Frontiers in Pharmacology</i> , 2021, 12, 803626.	1.6	1
23	First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 788569.	1.6	17
24	PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China. <i>Frontiers in Oncology</i> , 2021, 11, 745493.	1.3	2
25	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States. <i>Frontiers in Pharmacology</i> , 2021, 12, 736860.	1.6	4
26	Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2020, 40, 129-137.	1.1	39
27	Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. <i>Advances in Therapy</i> , 2020, 37, 847-859.	1.3	2
28	Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. <i>BMJ Open</i> , 2020, 10, e040691.	0.8	7
29	Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. <i>PLoS ONE</i> , 2020, 15, e0232240.	1.1	17
30	Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. <i>Clinical Therapeutics</i> , 2020, 42, 251-262.e5.	1.1	13
31	First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. <i>Cancer</i> , 2019, 125, 3526-3534.	2.0	87
32	Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. <i>Clinical Drug Investigation</i> , 2019, 39, 931-938.	1.1	27
33	Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. <i>Advances in Therapy</i> , 2019, 36, 3047-3058.	1.3	7
34	First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 491.	3.4	123
35	Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. <i>BMJ Open</i> , 2019, 9, e031019.	0.8	16
36	Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. <i>Breast</i> , 2019, 43, 1-6.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Subgroup Economic Evaluation of Radiotherapy for Breast Cancer After Mastectomy. <i>Clinical Therapeutics</i> , 2015, 37, 2515-2526.e5.	1.1	8
38	A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study. <i>PLoS ONE</i> , 2015, 10, e0121353.	1.1	33
39	Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis. <i>PLoS ONE</i> , 2014, 9, e88881.	1.1	20